Company Overview - HOPE Therapeutics Inc is a development stage healthcare delivery company focused on creating a network of interventional psychiatry clinics offering ketamine transcranial magnetic stimulation (TMS) and other therapies for suicidal depression and related disorders [1] - The company is developing a digital therapeutic-enabled platform to enhance the clinical benefits of NMDA-targeted drug therapy [1] - HOPE Therapeutics is a wholly-owned subsidiary of NRx Pharmaceuticals Inc [5] Key Developments - NRx Pharmaceuticals has initiated filing a New Drug Application for NRX-100 (IV ketamine) for treating suicidal depression based on clinical trial results from US National Institutes of Health and French health authorities data [2] - NRX-100 received Fast Track Designation from the US FDA for treating acute suicidality [2] - HOPE Therapeutics plans to acquire Kadima Neuropsychiatry Institute as its flagship clinic [3][5] - Dr David Feifel, founder of Kadima and a global leader in interventional psychiatry, is expected to join HOPE as Chief Medical Innovation Officer [3][6] Industry Insights - Ketamine treatment requires appropriate psychiatric supervision in controlled settings, as emphasized by Dr Feifel and supported by HOPE Therapeutics [7] - The recent death of Mathew Perry highlights the need for psychiatric centers of excellence providing ketamine and advanced treatments for depression [8] - Dr Feifel plans to bring his successful ketamine treatment methods from Kadima to the HOPE network [8] Parent Company Information - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing NMDA platform-based therapeutics for central nervous system disorders [9] - The company is developing NRX-101, an FDA-designated Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain [9] - NRx plans to file an NDA for Accelerated Approval of NRX-101 for bipolar depression with suicidality or akathisia [9] - NRX-101 has potential as a non-opioid treatment for chronic pain and complicated UTI [9]

Management believes uplisting has the potential to provide shareholders with improved liquidity Requires NRx Pharmaceuticals to meet certain listing requirements Company has advised NASDAQ that current shares outstanding is 15.7 millionWILMINGTON, Del., Jan. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced it has applied to NASDAQ to uplist the Company's securities to the NASDAQ Global Market (NASDAQ GM).Li ...

MIAMI, Jan. 10, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today announced it conducted an investor workshop to support planned expansion of HOPE's network of interventional psychiatry practices focused on the treatment of suicidal depression and PTSD, at the Mar-A-Lago Club in Palm Beach, FL. The event was attended by Qualified ...

Stocks with Buy Rank and Strong Momentum - NRx Pharmaceuticals, Inc (NRXP) has a Zacks Rank 1 and its current year earnings estimate increased by 46.2% over the last 60 days [1] - NRx Pharmaceuticals' shares gained 79.3% over the last three months compared to the S&P 500's 4.2% gain [1] - NRx Pharmaceuticals possesses a Momentum Score of A [1] - Pro-Dex, Inc (PDEX) has a Zacks Rank 1 and its current year earnings estimate increased by 40.9% over the last 60 days [2] - Pro-Dex's shares gained 67.7% over the last three months compared to the S&P 500's 4.2% gain [2] - Pro-Dex possesses a Momentum Score of A [2] - Puma Biotechnology, Inc (PBYI) has a Zacks Rank 1 and its current year earnings estimate increased by 24% over the last 60 days [3] - Puma Biotechnology's shares gained 10.9% over the last three months compared to the S&P 500's 4.2% gain [3] - Puma Biotechnology possesses a Momentum Score of A [3]

Core Insights - HOPE Therapeutics, Inc. has signed a Binding Term Sheet with Smith & Sauer, LLC for a $25 million equity purchase to fund planned clinic acquisitions, with additional $2 million investment in NRx Pharmaceuticals for drug applications [1][4][6] - The investment is expected to drive substantial revenue growth in HOPE clinic acquisitions during 2025, as forecasted by independent analysts [1][4] - Smith & Sauer's investment includes Series A Preferred Stock convertible into 1/3 of fully diluted HOPE equity, with a 15% preferred dividend and potential royalties up to $250 million [4][6] Company Overview - HOPE Therapeutics aims to develop a network of interventional psychiatry clinics offering innovative therapies for patients with suicidal depression and related disorders [8] - NRx Pharmaceuticals is focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression and chronic pain, with ongoing New Drug Applications for NRX-100 and NRX-101 [9][10] Strategic Partnership - The partnership with Smith & Sauer is aligned with addressing mental health challenges, particularly for military and veteran communities [2][3] - Smith & Sauer brings expertise in health information technology, which will be crucial for integrating HOPE's clinic network [3][7] Financial Details - The $25 million investment will be in Series A Preferred Stock, non-dilutive to NRx shareholders, and includes warrants for purchasing 3 million shares of NRx common stock at $3.00 per share [4][6] - Smith & Sauer will also purchase $2 million in NRx common stock at $2.75 per share, enhancing NRx's balance sheet value [4][6]

Dura Medical, with initial clinics in Naples and Fort Myers, to anchor the HOPE network in Florida Delivers a full range of precision psychiatry services, including Ketamine and Transcranial Magnetic Stimulation (TMS), to veteran and civilian residents of Florida Stephen Durand, founder of Dura, to serve as Director of Clinic Growth for HOPE in Florida Acquisition expected to be immediately accretive to revenue and EBITDA for NRx MIAMI, Jan. 6, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "C ...

MIAMI, Jan. 3, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) subsidiary, is inviting Qualified Institutional Investors to an investor workshop to support planned acquisitions for a national network of interventional psychiatry practices focused on treatment suicidal depression and PTSD. The Company has previously announced non-binding Letters of Intent and banking intent for initial clinic acquisitions and has disclosed its intent to acquire and integrate clinics ...

Aiming to be the first FDA-approved medication to treat suicidal depression Designed to help address the needs of the more than 13 million Americans who seriously consider suicide each year (CDC) Completion of NDA filing expected in the first quarter of 2025 Company to participate in 1x1 meetings in San Francisco during the Annual J.P. Morgan Healthcare Conference on January 13-16, 2025, in San Francisco, CA.  To schedule meetings, please contact [email protected] WILMINGTON, Del., Dec. 30, 2024 /PRNewswir ...

NRx Pharmaceuticals, Inc. (NRXP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a c ...

 WILMINGTON, Del., Nov. 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman, CEO and Chief Scientist will present at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.- on Tuesday December 3, 2024 at 1:00PM Eastern Standard Time. HOPE Therapeu ...